Effectiveness and Safety of Eptinezumab in Episodic and Chronic Migraine Headache in the UAE: A Retrospective Study.

Yazan BaderReem SulimanMohamad HarbVanessa SantosIbrahim Al QaisiTaoufik Alsaadi

Published in: Neurology and therapy (2023)

Patients enrolled in this trial experienced clinically significant reductions in MMD by month 6. Eptinezumab was well tolerated and with one AE of significance that led to discontinuation from the study.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
clinical trial
study protocol
open label
placebo controlled